Quarterly report pursuant to Section 13 or 15(d)

Segment Information (Schedule of Segment Information) (Details)

v3.21.1
Segment Information (Schedule of Segment Information) (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Segment Reporting Information [Line Items]      
Net Revenue $ 11,587 $ 12,918  
Direct cost of goods (3,908) (3,810)  
Sales and marketing costs (5,070) (4,679)  
Research and development (20,154) (15,117)  
General and administrative (12,472) (10,840)  
Other income (expense) 3,951 (2,540)  
Net loss (26,066) (24,068)  
Intangible asset, net 14,442 7,022 $ 14,629
Tangible assets 376,601 221,737  
Total assets 391,043 228,759 $ 328,834
Dermatology Products Sales [Member]      
Segment Reporting Information [Line Items]      
Net Revenue 10,719 11,946  
Direct cost of goods (3,908) (3,810)  
Sales and marketing costs (5,070) (4,679)  
Research and development 0 0  
General and administrative (1,156) (953)  
Other income (expense) (221) (207)  
Net loss 364 2,297  
Intangible asset, net 14,442 7,022  
Tangible assets 42,200 23,550  
Total assets 56,642 30,572  
Pharmaceutical and Biotechnology Product Development [Member]      
Segment Reporting Information [Line Items]      
Net Revenue 868 972  
Direct cost of goods 0 0  
Sales and marketing costs 0 0  
Research and development (20,154) (15,117)  
General and administrative (11,316) (9,887)  
Other income (expense) 4,172 (2,333)  
Net loss (26,430) (26,365)  
Intangible asset, net 0 0  
Tangible assets 334,401 198,187  
Total assets $ 334,401 $ 198,187